Conolidine’s analgesic effects stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors while in the central nervous system, conolidine modulates alternate molecular targets. A Science Advances analyze identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, w